Biotech Investor Alex Karnal: GLP-1 Drugs Signal ‘Trillion-Dollar Revolution' in Public Health [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
on the Invest Like the Best podcast that "2025 was probably the single most exciting year in my entire journey." The catalyst: GLP-1 medicines. His claim deserves scrutiny because the investment and personal health implications are substantial. A Trillion-Dollar Claim Worth Examining Karnal's argument has two parts. First, the commercial case: "This is a class of medicines that will easily be in excess of $100 billion a year in revenue." Second, the structural case: GLP-1 adoption is "the first commercial proof that we are ready for what I think we're gonna look back on in time as a once-in-a-lifetime trillion-dollar revolution in all of public health." He frames this not as a pharmaceutical success story but as a behavioral shift, with consumers "voting with their feet" to move from reactive disease treatment to proactive health protection. The structural case is harder to price: GLP-1 adoption as a behavioral shift toward proactive health is a compelling framework, but the tim
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly and Company (LLY) had its price target raised by Guggenheim from $1,163.00 to $1,183.00. They now have a "buy" rating on the stock.MarketBeat
- Novo Nordisk: Is The GLP-1 Golden Age Already Behind It? [Seeking Alpha]Seeking Alpha
- Neuroblastoma Treatment Market Analysis Report 2025-2035 - Regional Players and Local Manufacturers are Expected to Play an Important Role in Future Growth [Yahoo! Finance]Yahoo! Finance
- Here is why Eli Lilly (LLY) is Among the 8 Best Beginner Stocks to Buy Right Now [Yahoo! Finance]Yahoo! Finance
- Samsung Biologics Reports First Quarter 2026 Financial Results [TheStreet.com]TheStreet.com
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 4/21/26 - Form 4
- 4/21/26 - Form 4
- 4/21/26 - Form 4
- LLY's page on the SEC website